Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease
Status:
Recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine
extract (MediCabilis CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor
Neurone Disease. Participants will be randomised in a 1:1 ratio to receive MediCabilis CBD
Oil or placebo oil. The treatment duration is 6 months with one-month safety follow up.
Participants will be checked every month either face to face or via telephone and will be
assessed to collect data for study objectives such as ALSFRS-R, Forced Vital Capacity, pain
and spasticity score, and quality of life. Thirty (30) participants will be randomised.